Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | FPR2 | P25090 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15219632 | 0.77 | INMT (0.31) | — | |
| SCHEMBL7619079 | 0.75 | FPR2 (0.35) | GRM5GRM2KCNH2FPR2 | |
| SCHEMBL7619075 | 0.75 | FPR2 (0.35) | GRM5GRM2KCNH2FPR2 | |
| SCHEMBL7510369 | 0.75 | FPR2 (0.35) | GRM5GRM2KCNH2FPR2 | |
| SCHEMBL8394065 | 0.70 | FKBP1A (0.36) | — | |
| SCHEMBL6894808 | 0.67 | MEN1 (0.31) | — | |
| SCHEMBL22216460 | 0.67 | GRM5 (0.39) | GRM5NOTUMGRM2KCNH2 | |
| SCHEMBL8506958 | 0.67 | CHRM5 (0.45) | — | |
| SCHEMBL22216211 | 0.65 | GRM5 (0.38) | GRM5NOTUMGRM2 | |
| SCHEMBL7384750 | 0.64 | KDM4E (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040707-B2 | Bicyclic thiazoles as allosteric modulators of mGluR5 receptors | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-26 | — | — | US | disclosed |
| US-9040707-B2 | Bicyclic thiazoles as allosteric modulators of mGluR5 receptors | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-26 | — | — | US | disclosed |
| EP-2513117-B1 | BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-08-28 | — | — | EP | disclosed |
| US-20120258955-A1 | BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-10-11 | — | — | US | disclosed |
| US-20120258955-A1 | BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-10-11 | — | — | US | disclosed |
| WO-2011073339-A1 | BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258955-A1 | BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | GRM5, GRIK5, GRM2 | GRM5 1/4885NOTUM 2659/4885GRM2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.